Unveiling “S.H.E”: A Riveting Tale of Resistance and Survival in a Dystopian Future

Unveiling "S.H.E": A Riveting Tale of Resistance and Survival in a Dystopian Future

Stephen R Godfrey’s Debut Novel Paints a Harrowing Picture of Marginalized Women Fighting for Freedom in 2050

In a world reimagined and reshaped by societal upheavals, Stephen R. Godfrey’s debut novel, “S.H.E.”, takes readers on a gripping journey into a dystopian future where women are marginalized, and society is ruled by a harsh communist regime. Set in the summer of 2050, “S.H.E.” is a tale of defiance, courage, and resilience that captivates from the first page to the last.

Since the collapse of capitalist markets in the late 2030s, most of the world has embraced communist governments. In the United Kingdom, the regime is particularly oppressive, relegating women to domestic roles and enforcing hard labor on men in fields and mines. Against this backdrop, “S.H.E” tells the story of a group of brave women led by Jessica and Maggie who dare to challenge the status quo. Forming pockets of resistance in northern London, these women risk everything in their fight for justice and equality.

Stephen R Godfrey, a writer in his seventies, brings a wealth of life experience to his work. Having traveled extensively and witnessed various systems and ways of life, Godfrey infuses his novel with authenticity and depth. As the senior member of a large family with three children and nine grandchildren, Godfrey’s insights into familial bonds and societal roles add a profound layer to the narrative. His love for the English language and its nuances is evident in the rich, compelling prose that drives “S.H.E”.

What sets “S.H.E” apart is its relentless pace and the strength of its characters. Readers will find themselves deeply invested in the fates of Jessica, Maggie, and their fellow rebels as they navigate the dangers of their oppressive society. The novel is a poignant exploration of how dictatorial regimes can corrupt and exploit, presenting a chilling vision of a future that serves as a cautionary tale for the present.

“S.H.E” is not just a story of resistance; it is a stark reminder of the dangers of societal complacency and the power of solidarity. The book delves into themes of subjugation and the fight for a better future, making it a must-read for anyone interested in dystopian fiction, women’s rights, and political intrigue. The depiction of ‘breeding centres’ and the enforced separation of families is particularly harrowing, painting a vivid picture of the regime’s brutality.

About the Author:

After spending most of his life, working in Europe and the Middle East Stephen is now enjoying his retirement in the Wolds of Yorkshire in northern England and spends his time writing and playing the guitar. Back in the late sixties and early seventies, Stephen played in several rock bands and still enjoys listening to classic rock bands, including Led Zeppelin and The Smashing Pumpkins. Whilst this is his first published novel, he has a couple of projects on the go, one of which is the follow-up to S.H.E. (S.H.E. (2)). Stephen has a large family and is the proud ‘gramps’ to no less than nine grandchildren, which keeps him occupied when he’s not in his study writing.

Book Name: S.H.E

Author Name: Stephen R Godfrey

ISBN Number: 196378927X

Ebook Version: Click Here

Hardcover: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Global Publishing Agency
Email: Send Email
Phone: 5626141989
Address:5000 E Spring St
City: Long Beach
State: California 90815
Country: United States
Website: https://globalpublishingagency.com/

Genopets Launches New Apple Vision Pro App: Transforming Fitness and Digital Companionship

As the world becomes increasingly digital, finding compelling incentives to lead healthier lives is more crucial than ever. Enter Genopets, the mobile app that gamifies healthy habits, transforming self-care into a fun and rewarding adventure with a personalized digital companion. In Genopets, daily steps convert into Energy, helping players level up and evolve their pets while also leveling up themselves.

Introducing the Apple Vision Pro App

Genopets is committed to leveraging the latest technology to benefit players. The game economy is built on the blockchain, ensuring true ownership of in-game items. Currently, Genopets is developing a GenAI Adventure Mode to further motivate players to explore the real world and unlock a personalized AI lore of the Genoverse. To deepen the bonds players share with their Genopets, they have also developed a new companion app for the Apple Vision Pro.

https://youtu.be/cKFCRgbuja4 

The Apple Vision Pro app brings Genopets into the real world, allowing players to interact with them in a new dimension. Imagine watching movies with a Genopet or working beside one while it chills in its Habitat, like a digital terrarium. Viewing a Genopet in this way brings childhood dreams to life.

Features of the Apple Vision Pro App

–  360-Degree View: See digital pets from every angle.

–  Room Placement: Place a Genopet anywhere in any room.

–  Scalable Size: Scale them up to life-size or enjoy them in a floating Habitat.

Discover New Genopets

Explore unique Genopets without signing in. View randomly generated Genopets—each one different in stage, color, and Augments. Once a player scrolls past a Genopet, they won’t see it again, making each encounter unique and exciting. This feature allows players to explore the diverse possibilities within the Genoverse and get inspired to customize their own Genopet in the app using Cosmetic Crystals and Augments.

Future Enhancements

The current app developed for the Apple Vision Pro is just the beginning. The goal is to continue encouraging healthy habits with even more social and interactive features, including:

–  Pomodoro Timer: Audible reminders for stretch breaks.

–  Interactive Play: Feed, pet, and play with a Genopet using user touch and movements.

–  Social Engagement: Play with friends over SharePlay with Genopet races.

The Genopets team is incredibly excited about the potential of this new technology to expand the Genoverse and make the player experience more immersive and rewarding. Stay tuned for more updates as they continue to innovate and bring these digital companions to life in new ways.

About Genopets

Genopets is a mobile app that gamifies fitness, turning a player’s steps into Energy they can use to level up their digital pet and themself. Built on the blockchain, Genopets ensures true ownership of in-game items and offers an engaging way to stay active and healthy.

For more information, visit their website or check them out on X.

Media Contact
Company Name: Genopets
Contact Person: Maggie Dorfman
Email: Send Email
Country: United States
Website: https://www.genopets.me/

Non Muscle Invasive Bladder Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Non Muscle Invasive Bladder Cancer Research. Learn more about our innovative pipeline today! @ Non Muscle Invasive Bladder Cancer Pipeline Outlook

 

Key Takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report

  • June 2024:- Janssen Research & Development, LLC– Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy.
  • June 2024:- AstraZeneca– The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
  • June 2024:- SURGE Therapeutics- A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer. This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
  • June 2024:- Merck Sharp & Dohme LLC– A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676). This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B).
  • June 2024:- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins– This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
  • DelveInsight’s Non Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Non-Muscle Invasive Bladder Cancer treatment.
  • The leading Non Muscle Invasive Bladder Cancer Companies such as Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
  • Promising Non-Muscle Invasive Bladder Therapies such as TAR-200, Mitomycin C, Gemcitabine, TARA-002, Avelumab, RC48-ADC, STM-416, and others.

 

Stay informed about the cutting-edge advancements in Non Muscle Invasive Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Non Muscle Invasive Bladder Cancer Clinical Trials Assessment

 

Non Muscle Invasive Bladder Cancer Emerging Drugs Profile

  • TAR-200: TARIS Biomedical

TAR-200 is an investigational targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4 and NMIBC in SunRISe-1 and SunRISe-3. Currently, the drug is in Phase III stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

  • VAX 014: Vaxiion Therapeutics

VAX014 is a novel rBMC-based oncolytic immunotherapy designed to have distinct advantages over traditional and emerging oncolytic virotherapies. VAX014’s ability to specifically target both alpha3beta1(α3β1) and alpha5beta1 (α5β1) integrins facilitates broad spectrum activity against various solid tumor types because these two integrin family members are clinically validated as being selectively expressed or overexpressed in a wide variety of solid tumor indications (and most mouse models). Currently, the drug is in the Phase I stage of its development for the treatment of Non muscle-invasive bladder cancer.

  • SIM0237: Simcere Pharmaceutical Group

SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency-reduced IL-15/IL-15Rα sushi domain developed in-house by utilizing Simcere Zaiming’s protein engineering platform. As a bifunctional protein, the compound can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune activation to exhibit antitumor effect. The attenuated IL-15 part of SIM0237 increases MTD and avoids overstimulation and accompanied anergy of NK and CD8+ T cells. In the meantime, fusion of attenuated IL-15 to full anti-PD-L1 mAb further enhances the half-life of attenuated IL-15 and delivers IL-15 directly to the tumor microenvironment avoiding notorious CRS toxicity induced by systemic IL-15 exposure. Currently, the drug is in Phase I stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

 

Learn more about Non Muscle Invasive Bladder Cancer Drugs opportunities in our groundbreaking Non Muscle Invasive Bladder Cancer Research and development projects @ Non Muscle Invasive Bladder Cancer Unmet Needs

 

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Non Muscle Invasive Bladder Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Non Muscle Invasive Bladder Cancer Market Drivers and Barriers, and Future Perspectives

 

Non Muscle Invasive Bladder Cancer Companies and Drugs

  • Janssen Research & Development LLC:- TAR-200/Mitomycin C
  • Chengdu CoenBiotech Co., Ltd: BCG for therapeutics Use
  • SURGE Therapeutics:- STM-416
  • Pfizer:- PF-06801591
  • AstraZeneca: Durvalumab/BCG

 

Scope of the Non Muscle Invasive Bladder Cancer Pipeline Report

  • Coverage- Global
  • Non Muscle Invasive Bladder Cancer Companies- Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
  • Non-Muscle Invasive Bladder Therapies- TAR-200, Mitomycin C, Gemcitabine, TARA-002, Avelumab, RC48-ADC, STM-416, and others.
  • Non Muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non Muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Non Muscle Invasive Bladder Cancer Pipeline on our website @ Non Muscle Invasive Bladder Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive S ummary
  3. Non Muscle Invasive Bladder Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TAR-200: TARIS Biomedical
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. VAX 014: Vaxiion Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Non Muscle Invasive Bladder Cancer Key Companies
  21. Non Muscle Invasive Bladder Cancer Key Products
  22. Non Muscle Invasive Bladder Cancer- Unmet Needs
  23. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
  24. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
  25. Non Muscle Invasive Bladder Cancer Analyst Views
  26. Non Muscle Invasive Bladder Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Muscle Invasive Bladder Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Wet Age-Related Macular Degeneration Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet Age-Related Macular Degeneration therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline today! @ Wet Age-Related Macular Degeneration Pipeline Outlook

 

Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report

  • June 2024:- Outlook Therapeutics, Inc.– Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
  • June 2024:- Hoffmann-La Roche- This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
  • DelveInsight’s Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
  • The leading Wet Age-Related Macular Degeneration Companies such as OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.

 

Stay informed about the cutting-edge advancements in Wet Age-Related Macular Degeneration Treatments. Download for updates and be a part of the revolution in cancer care @ Wet Age-Related Macular Degeneration Clinical Trials Assessment

 

Wet Age-related Macular Degeneration Emerging Drugs

  • RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF.

  • 9MW 0211: Mabwell (Shanghai) Bioscience

9MW 0211 is a recombinant anti-VEGF humanized monoclonal antibody obtained based on rabbit monoclonal antibody and humanized transformation technology, which is a category 1 therapeutic biological product. It can specifically bind to the most active VEGF-A in the VEGF family, block its binding to receptors on the surface of endothelial cells, reduce vascular permeability and block the formation and development of new blood vessels, and reduce the leakage caused by new blood vessels, so as to achieve the purpose of treating eye diseases related to neovascularization such as neovascular (wet) age-related macular degeneration. The drug is currently being evaluated in Phase II/III clinical trial to treat patients with wet-AMD.

  • SYL1801: Sylentis

SYL1801 is a chemically modified siRNA, engineered using Sylentis proprietary SirFinder, which inhibits the synthesis of Nrarp. It is administered as an eye drop solution to transcriptionally down-regulate the expression of Nrarp, a target different from those against which the usual anti-angiogenic therapies based on anti-VEGF agents are directed. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with wet AMD.

  • OLX10212: OliX Pharmaceuticals

OLX10212 is a novel cell penetrating asymmetric small interference RNA being developed by OliX Pharmaceuticals in Phase I stage of development for the treatment of wet-MAD. OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD.

 

Learn more about Wet Age-Related Macular Degeneration Drugs opportunities in our groundbreaking Wet Age-Related Macular Degeneration Research and development projects @ Wet Age-Related Macular Degeneration Unmet Needs

 

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Wet Age-Related Macular Degeneration Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives

 

Wet Age-Related Macular Degeneration Companies and Therapies

  • Neuracle Genetics Inc.: NG101 AAV gene therapy
  • RemeGen Co. Ltd:- RC28-E
  • Outlook Therapeutics Inc.:- Bevacizumab/Ranibizumab

 

Scope of the Wet Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Wet Age-Related Macular Degeneration Companies- OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Wet Age-Related Macular Degeneration Pipeline on our website @ Wet Age-Related Macular Degeneration Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Wet Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RGX-314: REGENXBIO
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SYL1801: Sylentis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OLX10212: OliX Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Wet Age-related Macular Degeneration- Unmet Needs
  21. Wet Age-related Macular Degeneration- Market Drivers and Barriers
  22. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wet Age-Related Macular Degeneration Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA

HER2 Positive Breast Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in HER2 Positive Breast Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Breast Cancer Pipeline Outlook

 

Key Takeaways from the HER2 Positive Breast Cancer Pipeline Report

  • June 2024:- Latin American Cooperative Oncology Group– This study aims to identify HER2-positive early-stage breast cancer patients who could benefit from neoadjuvant treatment using PHESGO™ (pertuzumab and trastuzumab) without chemotherapy.
  • June 2024:- Seagen Inc.- This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
  • June 2024:- Institut Curie– This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.
  • June 2024:- Ambrx, Inc.- A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd. A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
  • June 2024:- Sichuan Baili Pharmaceutical Co., Ltd.- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer. This study is a phase II clinical trial to evaluate the safety and efficacy of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as first-line treatment in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
  • DelveInsight’s HER2 Positive Breast Cancer pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for HER2 Positive Breast Cancer treatment.
  • The leading HER2 Positive Breast Cancer Companies such as Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Promising HER2 Positive Breast Cancer Therapies such as Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, PHESGO, SHR-A1811, Pyrotinib, and others.

 

Stay informed about the cutting-edge advancements in HER2 Positive Breast Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Breast Cancer Clinical Trials Assessment

 

HER2 Positive Breast Cancer Emerging Drugs Profile

  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells.

  • HLX11: Shanghai Henlius Biotech

HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 Positive Breast Cancer.

  • MCLA-128: Merus N.V.

MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of HER2-positive metastatic breast cancer.

  • GQ1001: GeneQuantum

GQ1001 is a novel HER2-targeted antibody-drug conjugate (ADC) that was developed using innovative conjugation technologies coined intelligent Ligase-Dependent Conjugation (iLDC), that can significantly improves homogeneity and biostability of ADC. In preclinical studies, GQ1001 showed a robust anti-tumor response in multiple HER2+ models alone or in combination with HER2 TKIs and chemotherapeutics, and excellent pharmacokinetics and safety profiles in rats and monkeys due to low level of payload release. GQ1001 has already received Clinical Trial approval from the Therapeutic Goods Administration (TGA) in Australia and IND from FDA in USA. Currently the drug is in the Phase I stage of clinical trial evaluation for the treatment of HER2-positive metastatic breast cancer.

 

Learn more about HER2 Positive Breast Cancer Drugs opportunities in our groundbreaking Sq HER2 Positive Breast Cancer Research and development projects @ HER2 Positive Breast Cancer Unmet Needs

 

HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

HER2 Positive Breast Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in HER2 Positive Breast Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ HER2 Positive Breast Cancer Market Drivers and Barriers, and Future Perspectives

 

HER2 Positive Breast Cancer Companies and Therapies

  • M.D. Anderson Cancer Center: Zanidatamab/Letrozole/Tamoxifen
  • Seagen Inc.:- Tucatinibc/Trastuzumab/Pertuzumab
  • Sichuan Baili Pharmaceutical Co., Ltd.:- BL-M07D1/T-DM1
  • DualityBio Inc.:- DB-1303/BNT323/T-DM1
  • Ambrx Inc.;- ARX788

 

Scope of the HER2 Positive Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2 Positive Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • HER2 Positive Breast Cancer Therapies- Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, PHESGO, SHR-A1811, Pyrotinib, and others.
  • HER2 Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2 Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Breast Cancer Pipeline on our website @ HER2 Positive Breast Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2 Positive Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MCLA-128: Merus N.V.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GQ1001: GeneQuantum
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ES2B C001: ExpreS2ion Biotechnologies
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2 Positive Breast Cancer Key Companies
  21. HER2 Positive Breast Cancer Key Products
  22. HER2 Positive Breast Cancer- Unmet Needs
  23. HER2 Positive Breast Cancer- Market Drivers and Barriers
  24. HER2 Positive Breast Cancer- Future Perspectives and Conclusion
  25. HER2 Positive Breast Cancer Analyst Views
  26. HER2 Positive Breast Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2 Positive Breast Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Nasopharyngeal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Nasopharyngeal Cancer Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the Nasopharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nasopharyngeal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Nasopharyngeal Cancer Research. Learn more about our innovative pipeline today! @ Nasopharyngeal Cancer Pipeline Outlook

 

Key Takeaways from the Nasopharyngeal Cancer Pipeline Report

  • DelveInsight’s Nasopharyngeal Cancer pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Nasopharyngeal Cancer treatment.
  • The leading Nasopharyngeal Cancer Companies such as ProfoundBio, Chia Tai Tianqing Pharmaceutical Group, Takeda, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical, Ascentage Pharma Group, Akesa, and others.
  • Promising Nasopharyngeal Cancer Therapies such as Auto-Dendritic Adjuvant Therapy, Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Tislelizumab, SHR-1210, Zometa (zoledronic acid), AK105, Camrelizumab, and others
  • The Nasopharyngeal Cancer Companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The Nasopharyngeal Cancer therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.

 

Stay informed about the cutting-edge advancements in Nasopharyngeal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Nasopharyngeal Cancer Clinical Trials Assessment

 

Nasopharyngeal Cancer Emerging Drugs Profile

  • BL-B01D1: SystImmune

BL-B01D1 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by SystImmune, targeting both EGFR and HER3, proteins that are highly expressed in most epithelial tumors. The tetravalent BL-B01D1 possesses two binding domains blocking each Growth Factor Receptor, which both drive cancer cell proliferation and survival. Inheriting the SI-B001 mechanisms of action, BL-B01D1 effectively blocks EGFR and HER3 signals to cancer cells, thereby reducing proliferation and survival signals. Upon antibody-mediated internalization, BL-B01D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death. Currently, the drug is in Phase III stage of its clinical trial for the treatment of nasopharyngeal Carcinoma.

  • TAK-500: Takeda

TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of nasopharyngeal cancer.

  • APG-5918: Ascentage Pharma

APG-5918 is under development for the treatment of beta-thalassemia, metastatic solid tumors or relapsed or refractory non-Hodgkin’s Lymphoma, nasopharyngeal carcinoma, castration-resistant prostate cancer, B-cell non-Hodgkin lymphoma, IN1-negative malignant rhabdoid tumor, gastric cancer, ovarian clear cell carcinoma, mesothelioma, b cell lymphoma, sickle cell disease, diffuse large B cell lymphoma (DLBCL), SMARCB1-deficient malignant rhabdoid tumor,solid tumor, hematological tumor, anemia and unspecified indication. It is administered through oral route. It acts by targeting polycomb protein EED. Currently, the drug is in Phase I stage of clinical trial for the treatment of nasopharyngeal Carcinoma.

 

Learn more about Nasopharyngeal Cancer Drugs opportunities in our groundbreaking Nasopharyngeal Cancer Research and development projects @ Nasopharyngeal Cancer Unmet Needs

 

Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Nasopharyngeal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Nasopharyngeal Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Nasopharyngeal Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Nasopharyngeal Cancer Pipeline Report

  • Coverage- Global
  • Nasopharyngeal Cancer Companies- ProfoundBio, Chia Tai Tianqing Pharmaceutical Group, Takeda, Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical, Ascentage Pharma Group, Akesa, and others.
  • Nasopharyngeal Cancer Therapies- Auto-Dendritic Adjuvant Therapy, Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Tislelizumab, SHR-1210, Zometa (zoledronic acid), AK105, Camrelizumab, and others.
  • Nasopharyngeal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Nasopharyngeal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Nasopharyngeal Cancer Pipeline on our website @ Nasopharyngeal Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Nasopharyngeal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Nasopharyngeal Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Nasopharyngeal Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. BL-B01D1: SystImmune
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Drug name: Company name
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. APG-5918: Ascentage Pharma
  17. Drug profiles in the detailed report…..
  18. Preclinical Stage Products
  19. Drug Name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Nasopharyngeal Cancer Key Companies
  23. Nasopharyngeal Cancer Key Products
  24. Nasopharyngeal Cancer – Unmet Needs
  25. Nasopharyngeal Cancer – Market Drivers and Barriers
  26. Nasopharyngeal Cancer – Future Perspectives and Conclusion
  27. Nasopharyngeal Cancer Analyst Views
  28. Nasopharyngeal Cancer Key Companies
  29. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nasopharyngeal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Muddy Creek Records Announces Breakout Artist Ronnie Farmer Nation

Georgia Native Brings a Unique Blend of Blues, Rock, Country, and Rap to the Music Scene

Atlanta, GA – Muddy Creek Records is thrilled to introduce Ronnie Farmer Nation, a dynamic new artist making waves in the music industry with his eclectic blend of blues, rock, country, and rap. Ronnie Farmer Nation is a testament to the power of musical diversity and authenticity.

Georgia native Ronnie Farmer Nation developed his unique musical style while growing up on his family farm in East Texas. He began writing music in the eighth grade and made it his mission to become a legendary artist. Sponsored by Redneck Nation, Ronnie continues to pursue his dream of leaving a lasting impact on the music industry.

About Ronnie Farmer Nation

Ronnie Farmer Nation, a Georgia native, has emerged as a distinctive voice in the music world. His unique sound, influenced by his roots and a fusion of various genres, offers a refreshing take on contemporary music. His music reflects his life experiences, providing listeners with a raw and genuine insight into his journey.

Musical Journey

Growing up in the rural areas of Georgia, Ronnie was immersed in the rich musical traditions of the South. He absorbed the soulful melodies of blues, the rebellious spirit of rock, the heartfelt storytelling of country, and the rhythmic beats of rap. This diverse musical upbringing is evident in his work, creating a sound that is both unique and relatable.

Latest Release: “Country Boy”

Ronnie Farmer Nation’s latest single, “Country Boy,” encapsulates his musical ethos. The track blends soulful blues riffs with rock’s energy, country’s narrative depth, and rap’s modern edge. “Country Boy” is not just a song; it’s a story that resonates with anyone who understands the simplicity and complexity of rural life.

Follow and Listen

Fans can follow Ronnie Farmer Nation on his journey through his social media channels and music platforms:

A Word from Ronnie Farmer Nation

“I am a country man from the sticks, chasing my dreams through music. My songs are a window into my life, blending the old with the new, and I’m excited to share my story with the world,” says Ronnie. His music aims to bridge the gap between genres, creating a space where fans of all backgrounds can find common ground.

Upcoming Performances and Projects

Ronnie Farmer Nation is gearing up for a series of live performances across Georgia and neighboring states. Fans can expect an electrifying live show that brings his recorded music to life with an added layer of raw energy and authenticity.

In addition to live performances, Ronnie is working on new music that continues to push the boundaries of genre and storytelling. Each project aims to delve deeper into his personal narrative, offering listeners an even closer look at the man behind the music.

Muddy Creek Records: A Commitment to Authenticity

Muddy Creek Records is proud to support artists like Ronnie Farmer Nation, who bring authenticity and passion to their craft. The label is dedicated to nurturing talent that resonates with real-life experiences and connects with audiences on a personal level.

Follow Muddy Creek Records on Social Media

About Muddy Creek Records

Muddy Creek Records is a record label based in Atlanta, GA, dedicated to discovering and promoting artists who embody authenticity and musical diversity. The label’s mission is to support musicians who push the boundaries of genre and storytelling, bringing fresh and genuine sounds to the forefront of the music industry.

For additional information about Ronnie Farmer Nation and his music, please visit @officialmuddycreekrecords

Contact Information

For more information, interviews, or press inquiries, please contact:

Media Contact
Company Name: Muddy Creek Records Public Relations
Contact Person: Ronnie Farmer
Email: Send Email
Phone: (903) 368-9141
Country: United States
Website: https://www.instagram.com/officialmuddycreekrecords/

Trevor Atkinson’s New Book “Change Your Life in 30 Days: A Guide to Personal Transformation” Offers a Practical Roadmap to Transformative Change

Trevor Atkinson's New Book "Change Your Life in 30 Days: A Guide to Personal Transformation" Offers a Practical Roadmap to Transformative Change

Author Trevor Atkinson is excited to announce the release of his latest book, “Change Your Life in 30 Days: A Guide to Personal Transformation.” This empowering guide is designed to help readers embark on a transformative journey of self-discovery and growth, providing a structured and actionable approach to creating positive change in just 30 days.

“Change Your Life in 30 Days” takes readers on a step-by-step journey toward personal transformation. Atkinson’s book is grounded in psychology, mindfulness, and self-development practices, offering a comprehensive guide to help readers identify and overcome limiting beliefs, heal from past wounds, and cultivate a mindset of growth and resilience.

Key features of the book include:

  • Actionable Steps: Atkinson provides readers with daily tasks and exercises designed to facilitate self-awareness, reflection, and change.
  • Holistic Approach: The book addresses multiple facets of transformation, including emotional healing, cognitive reframing, and behavioral change.
  • Insightful Stories: Atkinson shares personal anecdotes and examples that illustrate the power of change, making the book relatable and engaging.
  • Compassionate Guidance: The book focuses on self-compassion and mindfulness and encourages readers to approach their transformation journey with kindness and understanding.
  • Transformative Tools: Readers will gain access to valuable tools and techniques, such as journaling prompts, mindfulness practices, and cognitive restructuring exercises.

Change Your Life in 30 Days” is a timely resource for anyone seeking to embark on a journey of personal growth and transformation. Atkinson’s clear, compassionate guidance and practical approach make the book accessible to readers of all backgrounds.

About the Author

Trevor Atkinson, an Honors degree Psychologist, Hypnotherapist and Master Practitioner of Neuro-Linguistic Programming, is a seasoned Mind coach with over a decade of experience. He empowers individuals to overcome obstacles and propel their lives forward, specializing in guiding transformative journeys. Having studied across Europe, North America, and Asia, Trevor’s expertise transcends borders. His counseling expertise extends to fostering healthy connections, aiding those grappling with personal challenges, and nurturing emotional well-being. Trevor’s approach encompasses understanding and overcoming life’s stressors, ensuring mental resilience. In his practice, he skillfully navigates clients through relational intricacies, empowering them to embark on meaningful self-discovery and fostering positive behavioral shifts.

Book Name: Change Your Life in 30 Days: A Guide to Personal Transformation

Author Name: Trevor Atkinson

ISBN Number: 1917238916

Ebook Version: Click Here

Paperback Version: Click Here

 

Media Contact
Company Name: Book Publishing Plus
Email: Send Email
Phone: +1-201-977-0753
Address:100 Overlook Center
City: Princeton
State: New Jersey
Country: United States
Website: https://bookpublishingplus.com/

Deepak Gupta’s “Success is a Choice” Wins Literary Titan Gold Book Award

Deepak Gupta’s self-help book, “Success is a Choice,” receives the prestigious Literary Titan Gold Book Award. The book offers a unique approach to success through a fictional story that empowers the readers with a practical framework to elevate their professional and personal lives and achieve their goals.

“Success is a Choice” takes readers on a journey with Dan Webber, an executive at a global company struggling to advance in his career. Frustrated by stagnation, Dan seeks guidance from his successful colleague, Ron Falcon. Through their interactions, Ron unveils the key concepts and skills that create success and differentiate winners. As Dan realizes, learns, and practices the new concepts and skills, he transforms not only himself and his work life but also his deteriorating personal relationships.

Deepak Gupta, a retired senior executive with over 50 years of global experience, draws upon his extensive career learnings to “demystify success.” He shatters conventional thinking and presents powerful, yet practical concepts woven into an engaging narrative. Gupta’s extensive experience and passion shine through in the accessible and succinct presentation of concepts designed to be inclusive of readers at any career stage—from beginners to seasoned professionals.

“Success Is a Choice, by Deepak Gupta, initially presents an ambitious premise that might appear to simplify life’s complexities,” states a Literary Titan review. “Yet, as one delves into the pages, the simplicity unfolds into a clear, actionable philosophy… Deepak Gupta’s keen observations and compelling writing style make this work not just a book but a resource for continuous reference.”

The book is a MUST READ for those who aspire to unlock their true potential and ignite transformation in their lives. Success isn’t merely a destination—it’s a continuous journey fueled by intentional choices. Whether you’re an aspiring entrepreneur, a business leader, a student, or someone navigating life’s twists and turns, this book offers practical wisdom and motivation. If you’re eager to dive into an enriching read, this award-winning guide can be ordered on Amazon and Barnes & Noble.

About the Book

The protagonist, Dan Webber, serves as an inspiring example of resilience, determination, and the power of conscious decisions. His story resonates with anyone seeking personal and professional transformation. As we follow Dan’s journey, we gain insights into the skills that separate winners and create a life of purpose and success.  

About the Author

Deepak Gupta is a visionary leader and accomplished author with over 50 years of international experience.  Having spent three decades at Procter & Gamble across multiple countries, his career trajectory is a testament to his dedication and success-driven mindset. Now, Gupta translates his extensive learnings and insights into empowering guides like “Success is a Choice.”  His passion lies in helping aspiring individuals unlock their full potential and achieve success.

Media Contact
Company Name: Literary Titan
Contact Person: Deepak Gupta
Email: Send Email
Country: India
Website: https://success-is-a-choice.com

Pure Parima Introduces New Ultra Sateen Body Pillows: The Ultimate in Luxury and Comfort

“Pure Parima Ultra Sateen Body Pillow”

Lumberton, New Jersey – Pure Parima, a leader in luxurious Egyptian cotton bedding, is thrilled to announce the launch of its new Ultra Sateen Body Pillows. This addition to the Ultra Sateen collection combines the simplicity of single-needle stitching with the exquisite sheen and softness of Pure Parima’s signature sateen fabric, now available in an oversized body pillow that comes pre-filled for ultimate convenience.

Experience unparalleled comfort with the Ultra Sateen Body Pillow, crafted from 100% certified extra long-staple Giza Egyptian cotton, sourced from the fertile Nile River valley. This premium fabric is known for its silky softness and exceptional durability, making it the perfect choice for a relaxing lounge experience.

“Our Ultra Sateen Body Pillows are designed to offer the highest level of comfort and luxury,” says Parima Ijaz, Founder of Pure Parima. “We have combined the finest Egyptian cotton with meticulous craftsmanship to create a product that not only feels incredible but also provides excellent value.”

The Ultra Sateen Body Pillow cover measures 44″ x 15″ + 1″ flange and comes with a pre-filled insert, eliminating the hassle of finding a suitable pillow insert. It is made with 100% certified extra long-staple Giza Egyptian cotton, recognized for its superior quality and softness. The pillow is Cotton Egypt Association™ certified and OEKO-TEX® certified for non-harmful chemicals, ensuring a safe and luxurious sleep experience. The elegant single-needle stitch design with a hidden zipper and flap enclosures provides a refined finish and ease of use.

Priced at $98, the Ultra Sateen Body Pillow offers exceptional value, especially in a market where few Egyptian cotton body pillows are available, and many do not come pre-filled. This product is an excellent addition to any bedroom, providing both aesthetic appeal and unmatched comfort.

Pure Parima is dedicated to providing the finest Egyptian cotton bedding, and the Ultra Sateen Body Pillow is a testament to this commitment. By combining high-quality materials with thoughtful design, Pure Parima continues to elevate the standard of luxury bedding.

The Ultra Sateen Body Pillow is now available for purchase on the Pure Parima website and at select retailers. For more information, please visit www.pureparima.com.

About Pure Parima

Pure Parima only purchases Egyptian cotton from certified growers, ensuring their product is the best option on the market. They are CEA certified, receiving this certification means their cotton is DNA tested to ensure authenticity. Consumers don’t have to read the fine print with Pure Parima, transparency and truth are their foundation. 

Media Contact
Company Name: Otter PR
Contact Person: Gabrielle Lask
Email: Send Email
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pure Parima Introduces New Ultra Sateen Body Pillows: The Ultimate in Luxury and Comfort